Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Details
Publication Year 2023-03-07,Volume 11,Issue #1,Page 25
Journal Title
Biomarker Research
Publication Type
Research article
Abstract
BACKGROUND: Activated immune cells (IC) in the tumor microenvironment (TME) are critical for anti-tumor efficacy. Greater understanding of the dynamic diversity and crosstalk between IC is needed to clarify their association with immune checkpoint inhibitor efficacy. METHODS: Patients from three tislelizumab monotherapy trials in solid tumors (NCT02407990, NCT04068519, NCT04004221) were retrospectively divided into subgroups by CD8(+) T-cell and macrophage (Mphi) levels, assessed via multiplex immunohistochemistry (mIHC; n = 67) or gene expression profiling (GEP; n = 629). RESULTS: A trend of longer survival was observed in patients with both high CD8(+) T-cell and Mphi levels versus other subgroups in the mIHC analysis (P = 0.11), which was confirmed with greater statistical significance in the GEP analysis (P = 0.0001). Co-existence of CD8(+) T cells and Mphi was coupled with elevated CD8(+) T-cell cytotoxicity, T-cell trafficking, MHC class I antigen presentation signatures/genes, and enrichment of the pro-inflammatory Mphi polarization pathway. Additionally, a high level of pro-inflammatory CD64(+) Mphi density was associated with an immune-activated TME and survival benefit with tislelizumab (15.2 vs. 5.9 months for low density; P = 0.042). Spatial proximity analysis revealed that closer proximity between CD8(+) T cells and CD64(+) Mphi was associated with a survival benefit with tislelizumab (15.2 vs. 5.3 months for low proximity; P = 0.024). CONCLUSIONS: These findings support the potential role of crosstalk between pro-inflammatory Mphi and cytotoxic T cells in the clinical benefit of tislelizumab. TRIAL REGISTRATION: NCT02407990, NCT04068519, NCT04004221.
Publisher
BioMed Central
Keywords
Immune cells; Immunotherapy; Macrophages; Tislelizumab; Tumor microenvironment
Department(s)
Medical Oncology
PubMed ID
36879284
Open Access at Publisher's Site
https://doi.org/10.1186/s40364-023-00465-w
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-11 06:23:42
Last Modified: 2023-07-11 06:25:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙